Together, these data indicate that AGAP1 is required for invasion in Pten‐null cells and that ovarian cancer patients with high ARF6 and AGAP1 levels, irrespective of the isoform of the AGAP1, have a poor clinical outlook. This evidence concerns the gene AGAP1 and ovarian cancer.